Longeveron Inc.

Longeveron Inc. announced that additional analysis of data from its Phase 2a clinical trial evaluating laromestrocel for mild Alzheimer's disease has been accepted for a poster presentation at the 2026 Alzheimer's Association International Conference (AAIC). The presentation is scheduled for July 13, 2026, in London. Previous results from the CLEAR MIND Phase 2a trial, supporting laromestrocel's therapeutic potential, were published in Nature Medicine in March 2025.

Longeveron Inc. announced it has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA). This designation provides significant benefits, including scientific advice, protocol assistance, and reduced administrative fees, aiming to accelerate drug development and patient access to treatments. The EMA's SME program has historically shown improved success rates for regulatory approvals, with SME marketing authorization applications reaching an 89% success rate in 2020.

Longeveron Inc. announced that its Chief Financial Officer, Lisa Locklear, will step down from her position effective July 10, 2026. Ms. Locklear is departing to pursue other professional and personal interests, and her resignation is not a result of any disagreement with the company. The company anticipates elevating its current controller, Marie Washburn, to the CFO role following Ms. Locklear's departure.

Longeveron Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on July 1, 2026. Key proposals include the election of three Class II directors, approval of an amendment to increase authorized Class A common stock from 84.3 million to 175 million shares, and an amendment to effect a reverse stock split of Class A and Class B common stock at a ratio between 1-for-2 and 1-for-20. Stockholders will also vote on amending the 2021 Incentive Award Plan and ratifying the appointment of CBIZ CPAs P.C. as the independent auditor.

Longeveron Inc. announced a strategic repositioning towards a capital-efficient model focused on securing licensing partnerships for its stem cell therapy, laromestrocel. The company successfully attracted new investment capital and completed a financing transaction in March 2026 for up to $30 million, with $15 million received upfront. Key upcoming milestones include top-line data from the Phase 2b HLHS trial in August 2026, which is eligible for a Priority Review Voucher, and the planned initiation of a Phase 2 PDCM trial in 2027.

Longeveron Inc. reported its first-quarter 2026 financial results, with a net loss of $4.7 million, an improvement from $5.0 million in Q1 2025. Revenues remained stable at $0.4 million. The company is on track to release top-line results from its Phase 2b clinical trial for Hypoplastic Left Heart Syndrome (HLHS) in August 2026. Longeveron also completed a private placement of $15 million, part of a larger $30 million deal, and is actively seeking strategic partnerships for its laromestrocel development programs.

Longeveron reported a net loss of $(4.7) million for the first quarter of 2026, an improvement from $(5.0) million in the same period last year. Cash and cash equivalents significantly increased to $15.8 million as of March 31, 2026, up from $4.7 million at December 31, 2025, primarily driven by $13.4 million from common and preferred stock issuance and $1.3 million from warrant exercises. Despite the increased cash, the company's cash flow forecast indicates insufficient funds to meet minimum expenditure commitments for one year, raising substantial doubt about its ability to continue as a going concern. Total revenues saw a slight increase to $398k, while operating expenses decreased.

Longeveron Inc. announced that the independent Data Monitoring Committee (DMC) completed its final prespecified data review for the fully enrolled Phase 2b clinical trial (ELPIS II) evaluating laromestrocel for hypoplastic left heart syndrome (HLHS). The DMC performed a risk-benefit assessment, identified no new safety concerns, and recommended the study continue as designed to completion. Top-line trial results are anticipated in August 2026.

Longeveron Inc. announced a Type C meeting with the U.S. FDA regarding its ELPIS II Phase 2b clinical trial for laromestrocel (LOMECEL-B®) in hypoplastic left heart syndrome (HLHS). The FDA stated that the trial's primary endpoint (RVEF) is not appropriate for demonstrating efficacy and, due to an ongoing interim analysis, a new primary endpoint could not be agreed upon while the trial is active. Consequently, the FDA no longer considers ELPIS II a pivotal trial, reversing its previous position from 2024. Despite this, the FDA expressed willingness to meet again after the trial's completion to discuss results and a potential path forward, suggesting objective measures like mortality and major adverse cardiac events (MACE) could be informative. Longeveron plans to submit a new Statistical Analysis Plan (SAP) with a composite primary endpoint and remains optimistic that trial results will support a Biologics License Application (BLA) filing following the anticipated top-line data readout in August 2026.

Longeveron Inc. announced a Type C meeting with the FDA regarding its ELPIS II clinical trial for hypoplastic left heart syndrome (HLHS). The FDA acknowledged the high unmet medical need but stated that the primary endpoint of right ventricle ejection fraction (RVEF) is not appropriate for demonstrating efficacy, and a new endpoint cannot be agreed upon while the trial is ongoing. Consequently, the FDA no longer considers ELPIS II a pivotal trial. However, the FDA expressed willingness to meet with Longeveron after the trial's completion to discuss results and a potential path forward, and Longeveron plans to submit a new statistical analysis plan. Top-line results for ELPIS II are expected in August 2026.